<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Orphan</title>
	<atom:link href="http://www.tapanray.in/tag/orphan/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>A Rare Strategic Acrobatic Feat in Covid Time</title>
		<link>http://www.tapanray.in/a-rare-strategic-acrobatic-feat-in-covid-time/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-rare-strategic-acrobatic-feat-in-covid-time</link>
		<comments>http://www.tapanray.in/a-rare-strategic-acrobatic-feat-in-covid-time/#comments</comments>
		<pubDate>Mon, 21 Dec 2020 00:00:09 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[acrobatic]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Alexion]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[comorbidity]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[feat]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[infected patients]]></category>
		<category><![CDATA[infection]]></category>
		<category><![CDATA[misdiagnosis]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[National Policy on rare diseases 2020]]></category>
		<category><![CDATA[new Coronavirus]]></category>
		<category><![CDATA[Orphan]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[rare diseases]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[time]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10376</guid>
		<description><![CDATA[‘Keep nose to the grindstone while lifting eyes to the hills.’ Quite a while ago, all-time global management guru – Peter Drucker used this essential acrobatic feat as an example, for the business strategists. This illustration signifies the criticality of harmonizing decisions &#8230; <a href="http://www.tapanray.in/a-rare-strategic-acrobatic-feat-in-covid-time/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-rare-strategic-acrobatic-feat-in-covid-time/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Reaping Rich Harvest With Orphan Drugs</title>
		<link>http://www.tapanray.in/reaping-rich-harvest-with-orphan-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=reaping-rich-harvest-with-orphan-drugs</link>
		<comments>http://www.tapanray.in/reaping-rich-harvest-with-orphan-drugs/#comments</comments>
		<pubDate>Mon, 21 Oct 2019 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[groups]]></category>
		<category><![CDATA[health for all]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Orphan]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[performance]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[quid pro quo]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reaping]]></category>
		<category><![CDATA[rich harvest]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9752</guid>
		<description><![CDATA[A set of perplexing questions on the drug industry has been haunting many, since long. One such area is intimately associated with the core purpose of this business, as enunciated by each company, often publicly. Just to give a feel &#8230; <a href="http://www.tapanray.in/reaping-rich-harvest-with-orphan-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/reaping-rich-harvest-with-orphan-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Making &#8216;National Policy For Rare Diseases&#8217; More Meaningful With &#8216;Orphan Drugs Act&#8217;</title>
		<link>http://www.tapanray.in/making-national-policy-for-rare-diseases-more-meaningful-with-orphan-drugs-act/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=making-national-policy-for-rare-diseases-more-meaningful-with-orphan-drugs-act</link>
		<comments>http://www.tapanray.in/making-national-policy-for-rare-diseases-more-meaningful-with-orphan-drugs-act/#comments</comments>
		<pubDate>Mon, 03 Jul 2017 00:00:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2017]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[CSTR]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[highlights]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[ODA]]></category>
		<category><![CDATA[Orphan]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8305</guid>
		<description><![CDATA[In November 2016, while hearing a related case, the Delhi High Court reportedly directed the Union Government to finalize and implement a policy on rare diseases, with a provision for free treatment with the expensive medications, as will be required by &#8230; <a href="http://www.tapanray.in/making-national-policy-for-rare-diseases-more-meaningful-with-orphan-drugs-act/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/making-national-policy-for-rare-diseases-more-meaningful-with-orphan-drugs-act/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“New drug prices are Astronomical, Unsustainable and Immoral” – Anatomy of Unique Protests</title>
		<link>http://www.tapanray.in/new-drug-prices-are-astronomicalunsustainable-and-immoral-anatomy-of-unique-protests/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-drug-prices-are-astronomicalunsustainable-and-immoral-anatomy-of-unique-protests</link>
		<comments>http://www.tapanray.in/new-drug-prices-are-astronomicalunsustainable-and-immoral-anatomy-of-unique-protests/#comments</comments>
		<pubDate>Mon, 06 May 2013 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[ACTH]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[anatomy]]></category>
		<category><![CDATA[astonishingly]]></category>
		<category><![CDATA[astronomical]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[center]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Conference]]></category>
		<category><![CDATA[Cowen]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[dutch]]></category>
		<category><![CDATA[economics]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[expensive]]></category>
		<category><![CDATA[HBR]]></category>
		<category><![CDATA[Hunter]]></category>
		<category><![CDATA[immoral]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Ireland]]></category>
		<category><![CDATA[kettering]]></category>
		<category><![CDATA[London]]></category>
		<category><![CDATA[LSE]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[memorial]]></category>
		<category><![CDATA[most]]></category>
		<category><![CDATA[Netherlands]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NewYork]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Orphan]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pompe]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[profiteering]]></category>
		<category><![CDATA[protests]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[researchers]]></category>
		<category><![CDATA[School]]></category>
		<category><![CDATA[Sloan]]></category>
		<category><![CDATA[Syndrome]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[Union]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[unsustainable]]></category>
		<category><![CDATA[upsurge]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2347</guid>
		<description><![CDATA[Yes. The quoted sentiment captured in the headline was reportedly voiced recently by many cancer specialists, including researchers and that too in the heartland of pharmaceutical innovation of the world– the United States of America. These specialist doctors argued: “High &#8230; <a href="http://www.tapanray.in/new-drug-prices-are-astronomicalunsustainable-and-immoral-anatomy-of-unique-protests/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/new-drug-prices-are-astronomicalunsustainable-and-immoral-anatomy-of-unique-protests/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Concept of Orphan Drugs for Orphan Diseases is Orphan in India</title>
		<link>http://www.tapanray.in/the-concept-of-orphan-drugs-for-orphan-diseases-is-orphan-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-concept-of-orphan-drugs-for-orphan-diseases-is-orphan-in-india</link>
		<comments>http://www.tapanray.in/the-concept-of-orphan-drugs-for-orphan-diseases-is-orphan-in-india/#comments</comments>
		<pubDate>Mon, 10 Sep 2012 00:00:07 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Concept]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Orphan]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=36</guid>
		<description><![CDATA[Though the percentage of patients suffering from ‘Rare Diseases’ in India is reportedly higher than the  world average, unfortunately even today such cases get little help from our government. According to experts, diseases manifesting patients representing maximum 6 to 8 &#8230; <a href="http://www.tapanray.in/the-concept-of-orphan-drugs-for-orphan-diseases-is-orphan-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-concept-of-orphan-drugs-for-orphan-diseases-is-orphan-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India needs ‘Orphan Drugs Act (ODA)’ to counter growing threat of dreaded rare diseases and simultaneously boost global growth potential of the Indian Pharmaceutical Industry</title>
		<link>http://www.tapanray.in/india-needs-orphan-drugs-act-oda-to-counter-growing-threat-of-dreaded-rare-diseases-and-simultaneously-boost-global-growth-potential-of-the-indian-pharmaceutical-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-needs-orphan-drugs-act-oda-to-counter-growing-threat-of-dreaded-rare-diseases-and-simultaneously-boost-global-growth-potential-of-the-indian-pharmaceutical-industry</link>
		<comments>http://www.tapanray.in/india-needs-orphan-drugs-act-oda-to-counter-growing-threat-of-dreaded-rare-diseases-and-simultaneously-boost-global-growth-potential-of-the-indian-pharmaceutical-industry/#comments</comments>
		<pubDate>Mon, 01 Nov 2010 00:30:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[boost]]></category>
		<category><![CDATA[counter]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[dreaded]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Growing]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[ODA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Orphan]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[simultaneous]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[threat]]></category>
		<category><![CDATA[to]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=354</guid>
		<description><![CDATA[An orphan disease is a rare and uncommon disease and an ‘Orphan Drug’ is a pharmaceutical substance that has been developed to treat an orphan disease. The US FDA defines a rare disease, with a prevalence of 1 in 5,000 &#8230; <a href="http://www.tapanray.in/india-needs-orphan-drugs-act-oda-to-counter-growing-threat-of-dreaded-rare-diseases-and-simultaneously-boost-global-growth-potential-of-the-indian-pharmaceutical-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-needs-orphan-drugs-act-oda-to-counter-growing-threat-of-dreaded-rare-diseases-and-simultaneously-boost-global-growth-potential-of-the-indian-pharmaceutical-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Orphan Drugs’ for ‘Orphan Diseases’ – is ‘Open Source Drug Discovery (OSDD)’ platform for discovery research the way forward?</title>
		<link>http://www.tapanray.in/orphan-drugs-for-orphan-diseases-is-open-source-drug-discovery-osdd-platform-for-discovery-research-the-way-forward/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=orphan-drugs-for-orphan-diseases-is-open-source-drug-discovery-osdd-platform-for-discovery-research-the-way-forward</link>
		<comments>http://www.tapanray.in/orphan-drugs-for-orphan-diseases-is-open-source-drug-discovery-osdd-platform-for-discovery-research-the-way-forward/#comments</comments>
		<pubDate>Sun, 22 Feb 2009 09:30:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CSIR]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[forward]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[Orphan]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[platform]]></category>
		<category><![CDATA[pool]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[source]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the way]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=962</guid>
		<description><![CDATA[To meet the unmet needs of common and dreaded diseases intensive R&#38;D activities are being undertaken by the Pharmaceutical Industry, the world over. At the same time, a percentage of human population, however small, also suffers from some rare diseases, &#8230; <a href="http://www.tapanray.in/orphan-drugs-for-orphan-diseases-is-open-source-drug-discovery-osdd-platform-for-discovery-research-the-way-forward/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/orphan-drugs-for-orphan-diseases-is-open-source-drug-discovery-osdd-platform-for-discovery-research-the-way-forward/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
